Pfizer (PFE) Total Debt (2009 - 2026)
Pfizer (PFE) posted quarterly Total Debt of $64.5 billion for Q1 2026, up 3.78% year-over-year from $62.1 billion in Q1 2025, and down 0.52% quarter-over-quarter from $64.8 billion in Q4 2025.
Pfizer (PFE) Total Debt (2009 - 2026) Analysis & Trends
Pfizer (PFE) has reported Total Debt for 18 consecutive years, with $64.5 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Debt rose 3.78% year-over-year to $64.5 billion; the TTM figure through Mar 2026 stood at $64.5 billion (up 3.78% YoY), while the FY2025 annual figure was $64.8 billion, up 0.69% from the prior year.
- Total Debt declined to $64.5 billion in Q1 2026 per PFE's latest filing, from $64.8 billion in the prior quarter.
- Across five years, Total Debt topped out at $72.4 billion in Q4 2023 and bottomed at $35.9 billion in Q2 2023.
- Historically, Total Debt has averaged $58.1 billion across 5 years, with a median of $64.4 billion in 2024.
- Annual changes were most pronounced in 2023 — Total Debt soared 101.28% — and 2024, when it dropped 11.06%.
- Pfizer's Total Debt stood at $35.9 billion in 2022, then soared by 101.28% to $72.4 billion in 2023, then retreated by 11.06% to $64.4 billion in 2024, then climbed by 0.69% to $64.8 billion in 2025, then retreated by 0.52% to $64.5 billion in 2026.
- Business Quant data shows PFE's Total Debt at $64.5 billion in Q1 2026, $64.8 billion in Q4 2025, and $61.7 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.51 Bn | 632.75 Bn | 17.26 Bn | 49.04 Bn |
| 2 | AbbVie | 470.28 Bn | 463.71 Bn | 12.70 Bn | 70.82 Bn |
| 3 | Merck | 378.50 Bn | 371.36 Bn | 12.21 Bn | 53.91 Bn |
| 4 | Novartis Ag | 302.91 Bn | 295.22 Bn | 11.24 Bn | 9.59 Bn |
| 5 | Astrazeneca | 259.04 Bn | 254.14 Bn | 12.86 Bn | 29.49 Bn |
| 6 | Amgen | 237.16 Bn | 223.17 Bn | 7.24 Bn | 62.75 Bn |
| 7 | Gilead Sciences | 183.02 Bn | 179.84 Bn | 6.22 Bn | 28.66 Bn |
| 8 | Pfizer | 160.85 Bn | 149.16 Bn | 10.94 Bn | 63.19 Bn |
| 9 | Gsk | 105.85 Bn | 101.69 Bn | 8.24 Bn | -25.96 Bn |
| 10 | Sanofi | 55.18 Bn | 47.80 Bn | 10.79 Bn | 25.19 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 63.19 Bn |
| Mar 29, 2026 | 64.46 Bn |
| Dec 31, 2025 | 64.80 Bn |
| Sep 28, 2025 | 61.71 Bn |
| Jun 29, 2025 | 61.80 Bn |
| Mar 30, 2025 | 62.11 Bn |
| Dec 31, 2024 | 64.35 Bn |
| Sep 29, 2024 | 67.70 Bn |
| Jun 30, 2024 | 69.45 Bn |
| Mar 31, 2024 | 69.54 Bn |
| Dec 31, 2023 | 72.35 Bn |
| Jul 2, 2023 | 65.34 Bn |
| Apr 2, 2023 | 35.89 Bn |
| Dec 31, 2022 | 35.95 Bn |
| Jul 3, 2022 | 40.28 Bn |
| Apr 3, 2022 | 36.30 Bn |
| Dec 31, 2021 | 38.24 Bn |
| Oct 3, 2021 | 39.88 Bn |
| Jul 4, 2021 | 39.24 Bn |
| Apr 4, 2021 | 39.70 Bn |